1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Withdrawn 1 |
Follow Hospitalization: new trials by email Literature Review of Hospitalization trials Research Report on Hospitalization
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19 Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir - Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19) | Phase 2 | Withdrawn | Pfizer | 2022-12-13 | 2023-03-01 |
COVID-19 (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Infections (1) · Lung Diseases (1) · Nidovirales Infections (1) · Pneumonia (1) · Pneumonia, Viral (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1) · Virus Diseases (1)
Ritonavir (1) · nirmatrelvir (1) · nirmatrelvir and ritonavir drug combination (1)
Pfizer (1)
Bulgaria (1) · United States (1)